Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection

被引:20
作者
Bombski, G
Gasiorowska, A
Orszulak-Michalak, D
Neneman, B
Kotynia, J
Strzelczyk, J
Janiak, A
Malecka-Panas, E
机构
[1] Med Univ Lodz, Dept Digest Tract Dis, PL-90153 Lodz, Poland
[2] Reg Hosp, Gastroenterol Ward, Piotrkow Trybunalski, Poland
[3] Med Univ Lodz, Dept Biopharm, PL-90153 Lodz, Poland
[4] Med Univ Lodz, Dept Gen & Transplantat Surg, PL-90153 Lodz, Poland
关键词
gastrin; carcinoembryonic antigen; cancer antigen 19-9; colorectal cancer;
D O I
10.1007/s00384-002-0420-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Gastrin stimulates mucosal growth of much of the gastrointestinal tract and has also been implicated in promoting growth of colonic tumors, but its role in colorectal carcinogenesis remains controversial. This study determined fasting serum gastrin levels before and after surgery for colorectal cancer (CRC) and the relationship to the clinical stage of the disease to investigate it possible prognostic role. Patients and methods: Fasting radioimmunoassay gastrin, CA 19-9, and CEA levels were measured before and after surgery for CRC. Helicobacter pylori status was also assessed since it causes significant hypergastrinemia. Results: Mean fasting plasma gastrin level was significantly higher in CRC patients than in controls before surgery but not 59 days after surgery. Mean CEA and CA 19-9 levels were significantly higher in patients with CRC before surgery than after tumor resection. There was a significant positive correlation between the plasma gastrin, CEA, and CA 19-9 levels and the CRC stage (Dukes' classification). Conclusion: The significance of gastrin as a marker for diagnosis or prognostic purposes in colorectal cancer needs to be further examined.
引用
收藏
页码:148 / 152
页数:5
相关论文
共 55 条
[1]  
BEGOS DG, 1994, J CLIN GASTROENTEROL, V18, P189
[2]  
Blum VF, 1997, HEPATO-GASTROENTEROL, V44, P1082
[3]  
BOLAND CR, 1991, J CLIN GASTROENTEROL, V13, P497
[4]  
CHARNLEY RM, 1992, ANN ROY COLL SURG, V74, P138
[5]   EXPRESSION, PROCESSING, AND SECRETION OF GASTRIN IN PATIENTS WITH COLORECTAL-CARCINOMA [J].
CICCOTOSTO, GD ;
MCLEISH, A ;
HARDY, KJ ;
SHULKES, A .
GASTROENTEROLOGY, 1995, 109 (04) :1142-1153
[6]   GASTRIN AND THE GROWTH OF THE GASTROINTESTINAL-TRACT [J].
EKUNDAYO, AA ;
LEE, CY ;
GOODLAD, RA .
GUT, 1995, 36 (02) :203-208
[7]   SERUM GASTRIN-LEVELS AND COLORECTAL NEOPLASIA [J].
ELEWAUT, A ;
VANDERSTRAETEN, E .
GASTROENTEROLOGY, 1995, 108 (02) :618-619
[8]  
FILELLA X, 1990, J NUCL MED ALLIED S, V34, P107
[9]   Considerations for long-term use of proton-pump inhibitors [J].
Garnett, WR .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (21) :2268-2279
[10]  
GUO YS, 1990, IN VITRO CELL DEV B, V26, P871